Higher urine-to-plasma urea ratio tied to increased risk of CKD progression: Study
USA: A study of a large cohort of patients with common forms of CKD (chronic kidney disease) found an independent association of the urine-to-plasma ratio of urea ([U/P]urea) with disease progression and incident kidney failure. The findings appeared in the American Journal of Kidney Diseases on November 07, 2022.
An association of urinary concentrating capacity with CKD progression, independently of glomerular filtration rate (GFR), supports the notion that a more comprehensive assessment of kidney function than is typically performed in clinical practice today, might improve risk prediction. The GFR, despite being the primary indicator of kidney function, does not fully capture the kidneys' state of health, even with the addition of albuminuria. In a large cohort of patients with common forms of CKD, researchers found that a lower [U/P]urea was associated with more rapid eGFR decline and the development of kidney failure independently of other major risk factors for CKD progression.
The key findings of the study were as follows:
- Median (interquartile range) [U/P]urea was 14.8. Compared to participants in the highest [U/P]urea quintile, those in the lowest quintile had a greater eGFR decline by 1.06 ml/min per 1.73m 2 per year over 7.0 years of follow-up.
- Each 1 standard deviation decrease in natural log-transformed [U/P]urea was independently associated with CKD progression (HR 1.22) and incident ESKD (HR 1.22). Associations differed by baseline eGFR.
- Among those with an eGFR ≥30 ml/min per 1.73m 2 , each 1 standard deviation decrease in log-[U/P]urea was independently associated with CKD progression (HR 1.30), but this was not significant among those with eGFR <30 ml/min per 1.73m 2 (HR 1.00).
Urea distinguishes itself from many other proposed biomarkers of tubular function by its central role in kidney physiology. Moreover, it is easily measured at a low cost in most clinical laboratories using standardized assays. Thus, [U/P]urea could represent an accessible marker of CKD progression, not only in ADPKD, but in forms of CKD with high prevalence.
Reference:
Jing Liu, Lise Bankir, Ashish Verma, Sushrut S. Waikar, Ragnar Palsson, Published:November 07, 2022DOI: https://doi.org/10.1053/j.ajkd.2022.09.010
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.